Health Canada Clears New Kidney Drug for IgA Nephropathy

Health Canada has approved Novartis's atrasentan, sold as Vanrafia, for reducing proteinuria, or excess protein in the urine, in adults with primary IgA nephropathy who are at risk of their disease progressing quickly. IgA nephropathy, sometimes called Berger's disease, is a kidney condition in which an antibody called immunoglobulin A builds up in the kidney's filtering units, triggering inflammation that can gradually damage kidney function over years. It's considered one of the more common causes of kidney failure driven by the immune system, and until recently, treatment options were limited mostly to blood pressure medications and steroids.

Atrasentan works by blocking the endothelin A receptor, a target that had not previously had an approved drug for this specific use. Blocking this receptor helps relax and protect the small blood vessels in the kidney's filtering structures, which in turn reduces the amount of protein leaking into the urine, a key marker doctors track to judge how much stress the kidneys are under and how quickly a patient's disease might progress. This approval specifically applies to adults with a urine protein-to-creatinine ratio of 1.5 grams per gram or higher, a threshold used to identify patients whose disease is likely to worsen without more aggressive treatment.

Novartis says the approval is based on results from a phase 3 study showing a statistically significant reduction in proteinuria, measured over a 24-hour urine collection, by week 36 of treatment compared to placebo. Atrasentan already holds accelerated approval from the FDA in the United States for the same use, so this Health Canada decision extends access to the drug for Canadian patients following a similar regulatory pathway. As with FDA accelerated approvals, continued approval is often tied to further confirmation that the reduction in proteinuria translates into a real slowing of kidney function decline over the longer term.

For patients with IgA nephropathy, particularly those already showing signs of more aggressive disease, this approval adds another treatment option that works through a genuinely different biological pathway than existing drugs like SGLT2 inhibitors or the recently approved complement inhibitors for this condition. Because IgA nephropathy often progresses slowly and silently over many years before causing noticeable symptoms, having more tools that specifically target proteinuria gives physicians more flexibility in trying to protect kidney function before permanent damage sets in. Patients with IgA nephropathy who are interested in this treatment should discuss with their nephrologist whether they meet the eligibility criteria and whether it's an appropriate addition to their current care plan.